Biostatistics Support
Gain stronger clarity in communication with the methodical biostatistics CRO services needed for drug development today!
The MMS team are all superstars! You have delivered to timelines throughout, and we really appreciate it. Thank you!
Expertise and regulatory insights set MMS apart.
Expert biostatisticians at MMS hold the trust of leading pharmaceutical and biotechnology Sponsors. Our biostatistics team has an incomparable, industry-educated skill set and end-game experience to provide support in:
- Sample size calculations,
- Randomization schedules,
- Statistical analysis plans (SAP),
- Data interpretation,
- Collaborative solution finding on data/analysis related hurdles, and much more.
When Sponsors engage an MMS biostatistician, they are guaranteed clarity in understanding the statistical rationale and excellent communication with all team members, including programmers, data management, data scientists, medical writers, and clinicians.
The success of a clinical trial depends on the strength and knowledge of the biostatistics lead. When supporting Sponsors with statistical analyses and protocol development for global health authority responses and/or publication support, the biostatisticians at MMS are experienced, attentive, methodical, and intuitive.
What Differentiates MMS From Other CROs?
responsive
MMS is more responsive, taking responsibility for the success of every project with consistent staff and proactive solutions that exceed the expectations of a CRO partner.
adaptable
MMS is more adaptable, knowing your satisfaction and top outcomes are dependent on our ability to remain nimble and make smart decisions based on scientifically-sound data.
focused
MMS is more focused, providing data-centric solutions and innovative technology and processes that help accelerate and de-risk the development and approval of your therapy.
Suggested For You
webinar
September 26th, 2024
Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance
regulatory intelligence
August 27th, 2024
Recent Guidance on Diversity Action Planning
regulatory intelligence
August 26th, 2024
Oncology Programs at the FDA
regulatory intelligence
August 26th, 2024
Three Key Take Reflections on the Recent Donanemab Approval
webinar
September 12th, 2024
No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology
regulatory intelligence
August 9th, 2024
FDA Updates 2024 Language Access Plan
regulatory intelligence
August 3rd, 2024
EMA Launches New Pilot Program for Orphan Medical Devices
perspectives
July 30th, 2024
The Critical Role of Quality Control (QC) – Medical Writing and Beyond
regulatory intelligence
July 26th, 2024
Key Decision Points for Recent Oncology Approvals
regulatory intelligence
July 24th, 2024
Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products
perspectives
July 23rd, 2024
PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma
news
July 17th, 2024
Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization